BBH vs XBI

BBHBVanEck Biotech ETF

XBIAState Street SPDR S&P Biotech ETF

In short

BBH Biotech, distilled. BBH tracks an index of around 25 US-listed drug and diagnostics companies, so each name carries real weight instead of getting lost in a crowd. Running since 2011, at a fee below the typical biotech fund.

XBI Biotech's great leveler. Its index weights roughly 160 US biotechs near-equally, so a clinical-stage minnow carries about as much as a megacap. Live since 2006 and one of the most heavily traded funds in the sector.

Stated mandate

BBH The fund seeks to track, before fees and expenses, the price and yield performance of the MVIS US Listed Biotech 25 Index. That index represents companies involved in developing, producing, marketing, and selling drugs based on genetic analysis and diagnostic equipment.

XBI The fund seeks to track, before fees and expenses, the total return performance of the S&P Biotechnology Select Industry Index.

Why people hold it

• BBH 0.35% a year, below the 0.50% typical for biotech funds and level with XBI.
• Around 25 holdings, so the leaders in the index actually move the fund rather than getting diluted across hundreds of tickers.
• Rules-based: it follows the MVIS US Listed Biotech 25 Index, no manager guessing which drug pipeline pans out.vaneck.com
• Trading since 2011, through several full biotech cycles, and it sits in the upper half of its biotech peer group.

• XBI Modified equal weighting spreads exposure across roughly 160 biotechs instead of a handful of giants, so small drug developers actually move the fund.ssga.com
• 0.35% a year sits below the typical fee in its biotech peer group, which is unusual for a specialist sleeve this narrow.
• Among the most heavily traded funds in biotech and multi-billion-dollar in size, so getting in and out is rarely the hard part.
• A 2006 launch from State Street's SPDR line, meaning it has traded through several biotech booms and busts rather than one hot cycle. Pays quarterly.

Worth knowing

• BBH Concentration cuts both ways: with roughly 25 names, one failed trial or patent cliff lands hard.
• One of the less-traded funds in the biotech aisle, so bid-ask spreads deserve attention. Limit orders are the usual fix.
• Not the cheapest seat in the category: IBBQ charges 0.19%.

• XBI Equal weighting leans hard on smaller, clinical-stage names where a single trial readout moves a stock, so swings run deeper than cap-weighted rivals like IBB.ssga.comnasdaqomx.com
• Not the cheapest ticket on the shelf: Invesco's IBBQ charges 0.19% against XBI's 0.35%.
• One US industry only, drawn from the biotechnology segment of the S&P Total Market Index, so it can drift a long way from the broad market either direction.ssga.com

Full BBH profile⁠

Full XBI profile⁠